Cipla exploring new customer deals for its China factory: Executive
Shanghai: Indian pharmaceutical giant Cipla is exploring entry into at least two new international markets for products manufactured at its factory in Jiangsu province, China, as part of a broader strategy to work around constrained production capacity in India.
The factory making inhalation respule products, began operations in 2024 and was initially set up to cater to the U.S. market.
"Sometimes we face capacity restrictions ... so they (customers) do approach us whether we can handle the supplies," Deepak Hegde, Cipla's general manager for China, told Reuters.
He said the company was in talks with "at least two or three different countries", for product shipments from China and those discussions began around six or eight months ago.
He declined to say how much it had supplied to the United States from the Chinese manufacturing site or name the other countries it was in discussions with.
The Chinese site can produce about 55 million units annually of products used in inhalers, Hegde said.
Separately, in May, the Medical Dilaogues team reported that Jay Precision Pharmaceuticals Private Limited, a subsidiary of Cipla, will acquire 26% stake on fully diluted basis in AMPIN Energy C&I Eighteen Private Limited.
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: Cipla Gets CDSCO Panel Nod To BE Study, Phase III Trial of Semaglutide for Weight Management
Next Story